Zhejiang Conba Pharmaceutical Co.,Ltd. predicted a yearly growth of 70% for net profit attributable to shareholders in the first three quarters of 2013, due to increasing sales revenue that has boosted prime operating profit.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.43 CNY | +1.31% | +4.62% | +7.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.52% | 1.88B | |
+19.64% | 42.33B | |
+21.25% | 22.47B | |
+18.92% | 15.25B | |
+53.19% | 12.6B | |
-0.05% | 6.79B | |
-11.11% | 6.71B | |
-8.87% | 5.73B | |
+14.27% | 5.47B | |
+6.91% | 4.78B |
- Stock Market
- Equities
- 600572 Stock
- News Zhejiang CONBA Pharmaceutical Co.,Ltd.
- Zhejiang Conba Pharmaceutical Co.,Ltd. Provides Earnings Guidance the First Nine Months of 2013